Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
Points and comments are a snapshot, not live.
Moderna and Merck's mRNA cancer vaccine cut melanoma death or recurrence by 42% in a Phase 3 trial.
The personalized mRNA vaccine intismeran (mRNA-4157), combined with Merck's Keytruda, reduced risk of recurrence or death by 42% versus Keytruda alone in a Phase 3 trial of 1,137 patients with resected stage IIB-IV melanoma. After two years, 82% of the combination group were alive without recurrence versus 70% on standard treatment. The vaccine encodes up to 34 mutations from each patient's tumor. Companies are engaging regulators for approval.
The results, presented at the European Society of Medical Oncology, are a significant advance for melanoma treatment and bolster hopes for mRNA-based cancer therapies.
What commenters are saying
Commenters broadly view the results as promising and significant, with some noting the stock drop on the news reflects high expectations rather than disappointment. A key correction emerges: one commenter initially blamed cancer medication for a parent's death, but after discussion realized the liver cancer was unrelated and found closure. Others caution against misinterpreting anecdotal evidence. A subthread debates whether the Trump administration and RFK Jr. oppose mRNA vaccines, with skeptics questioning the motives and citing past vaccine support.